ALNY News and Press, Alnylam Pharmaceuticals Inc. From 07/28/22

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer...

Trading in Bausch Health Companies ( BHC ) was briefly halted Thursday morning and is currently down 50 % after a Delaware federal court judge issued an oral order on patent litigation over Xifaxan. Judge Richard Andrews has directed Bausch ( BHC ) subsidiary S...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) stock is trading in the green July 28 despite Q2 results missing street estimates, but the RNAi therapy maker has reiterated its FY22 outlook. Non-GAAP net loss widened to -$245.83M, compared to -$153.05M in Q1 2021. Tota...

Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q2 Non-GAAP EPS of -$2.03 misses by $0.69 . Revenue of $224.82M (+1.9% Y/Y) misses by $31.24M . Cash, cash equivalents and marketable securities were $2.11 billion as of June 30, 2022, compared to $2.44 bi...

− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® (33% Growth vs. Same Period Last Year) – − Received FDA Approval of AMVUTTRA™ (vutrisiran) f...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$1.34 (-3.1% Y/Y) and the consensus Revenue Estimate is $256.06M (+16.1% Y/Y). Over the last 2 years, ALNY ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ), a biotech focused on RNAi therapeutics, announced on Wednesday its plans to pursue a cardiometabolic candidate based on mutations in the INHBE gene after a study led to supportive data. The development plan follows the research of ...

- Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes - - Alnylam to Pursue INHBE as a Therapeu...

A committee of the European Medicines Agency ( EMA ) recommended the approval of Alnylam Pharmaceuticals' ( NASDAQ: ALNY ) RNAi therapy Amvuttra (vutrisiran) to treat hereditary transthyretin-mediated (hATTR) amyloidosis in adults patients with stage 1 or sta...